In clinical trials, approximately 70% of participants reportedly exhibited adverse events, primarily gastrointestinal symptoms, such as diarrhea and nausea
CWR reports payments to the institution from the Irish Research Council, Health Research Board, Science Foundation Ireland, and Anabio
Real-world evidence from observational studies consistently shows that GLP-1 RA use is associated with reduced risk of hepatic decompensation even in patients with established cirrhosis, supporting cautious use in this population
Aim for frequent, small meals: Since semaglutide suppresses appetite, it may be better to eat frequent, small meals (as opposed to three large meals)
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH